GigaMune, Inc. is a San Francisco-based biotechnology company specializing in the development of in vivo cell therapies for cancer and inherited blood disorders. Their innovative approach involves infusing virus-like gene delivery particles directly into patients to address manufacturing bottlenecks and improve patient access to treatments.
Founded by a team of experienced entrepreneurial scientists, GigaMune is at the forefront of rethinking cell therapy by utilizing novel technologies for molecular targeting, including artificial intelligence and high-throughput genomics. Their pipeline includes in vivo cell therapies for conditions such as multiple myeloma, acute myeloblastic leukemia, and sickle cell disease, with a focus on enhancing efficacy while minimizing medical risks associated with traditional lymphodepletion methods.
Generated from the website